Literature DB >> 6927281

Penetration of moxalactam and cefazolin into atrial appendage after simultaneous intramuscular or intravenous administration.

R E Polk, J E Smith, K Ducey, R R Lower.   

Abstract

This study compared the penetration of moxalactam and cefazolin into the human atrial appendage after simultaneous administration of both drugs by two routes. Nineteen adult patients scheduled for coronary vein bypass surgery randomly received 10 mg of moxalactam and cefazolin per kg by either the intramuscular or intravenous (bolus) route on administration of anesthesia. Concentrations of cefazolin in serum were significantly greater than concentrations of moxalactam at all times for both routes of administration. There were no significant differences, however, in the concentration of these drugs in atrial appendages, although concentrations of both agents administered intravenously were significantly greater than of drugs administered intramuscularly. (19.3 +/- 10.3 and 21.0 +/- 11.0 micrograms intravenously versus 8.3 +/- 3.6 and 10.1 +/- 3.2 micrograms/g intramuscularly for moxalactam and cefazolin, respectively).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6927281      PMCID: PMC183710          DOI: 10.1128/AAC.22.2.201

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

2.  Measurement of serum and tissue concentration of moxalactam using high pressure liquid chromatography.

Authors:  W F Diven; B D Obermeyer; R L Wolen; V L Yu; J Lyon; J Zuravleff
Journal:  Ther Drug Monit       Date:  1981       Impact factor: 3.681

Review 3.  Pharmacokinetics of tissue penetration of antibiotics.

Authors:  T Bergan
Journal:  Rev Infect Dis       Date:  1981 Jan-Feb

4.  Effect of protein binding on the penetration of nonmetabolized cephalosporins into atrial appendage and pericardial fluids in open-heart surgical patients.

Authors:  C H Nightingale; J J Klimek; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

5.  Pharmacokinetics, protein binding, and predicted extravascular distribution of moxalactam in normal and renal failure subjects.

Authors:  L R Peterson; B Bean; C E Fasching; W P Korchik; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

6.  Cefazolin and moxalactam pharmacokinetics after simultaneous intravenous infusion.

Authors:  R E Polk; B J Kline; S M Markowitz
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

7.  In vitro activity of LY127935.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191

  7 in total
  2 in total

Review 1.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

2.  Cefazolin potency against methicillin-resistant Staphylococcus aureus: a microbiologic assessment in support of a novel drug delivery system for skin and skin structure infections.

Authors:  David P Nicolau; Barry N Silberg
Journal:  Infect Drug Resist       Date:  2017-07-26       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.